August 9th 2025
Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies
1.0 Credit / Immunology, Pulmonology/Respiratory
View More
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
View More
Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage
1.5 Credits / Immunization, Infectious Disease, Pulmonology
View More
Reflecting on the Real-World Use of Biologic Therapy in Asthma Management
1.5 Credits / Immunology, Pulmonology
View More
Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists
1.5 Credits / Pulmonology
View More
Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies
1.5 Credits / Pulmonology, Cardiology, Rare Diseases
View More
Patient Response to Pirfenidone, Nintedanib for IPF Differs in Real World vs Trials
July 24th 2024While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world settings.
Read More
A Breathtaking Crisis, Part 2: Climate Change Worsens Asthma for Underserved Communities
July 3rd 2024Underserved communities, already facing higher asthma prevalence due to social determinants of health, are disproportionately affected by the impact climate change is having on asthma exacerbations. Potential solutions include education for patients and health care providers, climate litigation to establish environmental rights, and policy changes to curb climate change.
Read More
Dr Paul Frohna Details Plans for Further Research on ENV-101 for IPF
June 24th 2024The ENV-101 phase 2a trial for idiopathic pulmonary fibrosis (IPF) focused on assessing safety, lung function, and fibrosis, with plans for further trials, combination therapies, and strategies to manage adverse effects.
Read More
Other Challenges With Bronchiectasis and Key Takeaways
May 8th 2024An exploration of idiopathic bronchiectasis, emphasizing the importance of patient participation in clinical trials to advance knowledge and treatment options for this condition, along with concluding thoughts and key takeaways on the management and understanding of bronchiectasis.
Watch
What We’re Reading: RSV Vaccine Demand; Permanent Contraception; Drug Negotiation Impact
December 8th 2023The Biden administration recently met with manufacturers of respiratory syncytial virus (RSV) immunizations to encourage them to increase access to the vaccine; since the Dobbs v Jackson decision, many patients have been seeking more permanent reproductive health care solutions; a Mathematica analysis showed that Medicare prescription drug price negotiations could have cut seniors’ out-of-pocket costs by nearly a quarter had the program been in effect in 2021.
Read More
Dr Parth Rali Explains Challenges of Managing Intermediate-Risk Pulmonary Embolism
November 20th 2023Dr. Parth Rali, MD, of Temple University Hospital explained the challenges of managing patients with intermediate-risk pulmonary embolism (PE) and how risk stratification tools can help to address these challenges.
Watch